| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis PS Dulai, S Singh, J Patel, M Soni, LJ Prokop, Z Younossi, G Sebastiani, ... Hepatology 65 (5), 1557-1565, 2017 | 1746 | 2017 |
| Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease R Loomba, V Seguritan, W Li, T Long, N Klitgord, A Bhatt, PS Dulai, ... Cell metabolism 25 (5), 1054-1062. e5, 2017 | 935 | 2017 |
| Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis R Khera, MH Murad, AK Chandar, PS Dulai, Z Wang, LJ Prokop, ... Jama 315 (22), 2424-2434, 2016 | 921 | 2016 |
| Natural history of adult ulcerative colitis in population-based cohorts: a systematic review M Fumery, S Singh, PS Dulai, C Gower-Rousseau, L Peyrin-Biroulet, ... Clinical Gastroenterology and Hepatology 16 (3), 343-356. e3, 2018 | 439 | 2018 |
| Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes S Singh, PS Dulai, A Zarrinpar, S Ramamoorthy, WJ Sandborn Nature reviews Gastroenterology & hepatology 14 (2), 110-121, 2017 | 379 | 2017 |
| MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice PS Dulai, CB Sirlin, R Loomba Journal of hepatology 65 (5), 1006-1016, 2016 | 365 | 2016 |
| First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis S Singh, MH Murad, M Fumery, PS Dulai, WJ Sandborn Clinical Gastroenterology and Hepatology 18 (10), 2179-2191. e6, 2020 | 324 | 2020 |
| The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn’s disease: results from the US VICTORY Consortium PS Dulai, S Singh, X Jiang, F Peerani, N Narula, K Chaudrey, ... Official journal of the American College of Gastroenterology| ACG 111 (8 …, 2016 | 322 | 2016 |
| Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease S Singh, NS Ding, KL Mathis, PS Dulai, AM Farrell, JH Pemberton, ... Alimentary pharmacology & therapeutics 42 (7), 783-792, 2015 | 190 | 2015 |
| Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management PS Dulai, WJ Sandborn, S Gupta Cancer prevention research 9 (12), 887-894, 2016 | 187 | 2016 |
| Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis S Singh, A Facciorusso, PS Dulai, V Jairath, WJ Sandborn Clinical Gastroenterology and Hepatology 18 (1), 69-81. e3, 2020 | 185 | 2020 |
| Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts L Tsai, C Ma, PS Dulai, LJ Prokop, S Eisenstein, SL Ramamoorthy, ... Clinical Gastroenterology and Hepatology 19 (10), 2031-2045. e11, 2021 | 184 | 2021 |
| Risks of serious infection or lymphoma with anti–tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review PS Dulai, KD Thompson, HB Blunt, MC Dubinsky, CA Siegel Clinical Gastroenterology and Hepatology 12 (9), 1443-1451, 2014 | 177 | 2014 |
| Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses BS Boland, Z He, MS Tsai, JG Olvera, KD Omilusik, HG Duong, ES Kim, ... Science immunology 5 (50), eabb4432, 2020 | 168 | 2020 |
| Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity RH Mills, PS Dulai, Y Vázquez-Baeza, C Sauceda, N Daniel, RR Gerner, ... Nature microbiology 7 (2), 262-276, 2022 | 164 | 2022 |
| Open: Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ... Official journal of the American College of Gastroenterology| ACG 113 (9), 1345, 2018 | 153 | 2018 |
| Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis M Fumery, PS Dulai, S Gupta, LJ Prokop, S Ramamoorthy, WJ Sandborn, ... Clinical Gastroenterology and Hepatology 15 (5), 665-674. e5, 2017 | 150 | 2017 |
| Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis H Yoon, S Jangi, PS Dulai, BS Boland, LJ Prokop, V Jairath, BG Feagan, ... Gastroenterology 159 (4), 1262-1275. e7, 2020 | 142 | 2020 |
| Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases C Abraham, PS Dulai, S Vermeire, WJ Sandborn Gastroenterology 152 (2), 374-388. e4, 2017 | 135 | 2017 |
| Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease PS Dulai, BS Boland, S Singh, K Chaudrey, JL Koliani-Pace, G Kochhar, ... Gastroenterology 155 (3), 687-695. e10, 2018 | 134 | 2018 |
